DOI QR코드

DOI QR Code

CCR5 Polymorphism as a Protective Factor for Hepatocellular Carcinoma in Hepatitis B Virus-Infected Iranian Patients

  • Abdolmohammadi, Reza (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences) ;
  • Azar, Saleh Shahbazi (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences) ;
  • Khosravi, Ayyoob (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences) ;
  • Shahbazi, Majid (Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences)
  • Published : 2016.10.01

Abstract

The CC chemokine receptor 5 (CCR5) delta 32 allele results in a nonfunctional form of the chemokine receptor and has been implicated in a variety of immune-mediated diseases. $CCR5{\Delta}32$ may also predispose one to chronic liver disease or be linked with resistance to HBV infection. This study was undertaken to investigate any association between CCR5 polymorphism with resistance to hepatitis B or susceptibility to HBV infection. A total of 812 Iranian individuals were enrolled into two groups: HBV infected cases (n=357), who were HBsAg-positive, and healthy controls (n=455). We assessed polymorphisms in the CCR5 gene using specific CCR5 oligonucleotide primers surrounding the breakpoint deletion. Genotype distributions of the HBV infected cases and healthy controls were determined and compared. The CCR5/CCR5 (WW) and $CCR5/CCR5{\Delta}32$ (W/D) genotypes were found in (98%) and (2%) of HBV infected cases, respectively. The $CCR5{\Delta}32/{\Delta}32$genotype was not found in HBV infected cases. Genotype distributions of CCR5 in healthy controls were W/W genotype in (87.3%), W/D genotype in (11.2%) and D/D genotype in (1.5%). Heterozygosity for $CCR5/CCR5{\Delta}32$ (W/D) in healthy controls was greater than in HBV infected cases (11.2% vs 2%, p < 0.001). W/D and D/D genotypes were more prominent in healthy controls than in HBV infected cases. This study provides evidence that the $CCR5{\Delta}32$ polymorphism may have a protective effect in resistance to HBV infection at least in the Iranian population.

Keywords

CC chemokine receptor 5;chemokine receptor;disease susceptibility;hepatitis B virus

Acknowledgement

Supported by : Golestan University of Medical Science

References

  1. Ahn SH, Kim do Y, Chang HY, et al. (2006) Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J Med Virol, 78, 1564-71. https://doi.org/10.1002/jmv.20739
  2. Ajuebor MN, Aspinall AI, Zhou F, et al (2005). Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J Immunol,174, 8027-37. https://doi.org/10.4049/jimmunol.174.12.8027
  3. Attar M, Azar SS, Shahbazi M. (2015) Interleukin-6-174 promoter polymorphism and susceptibility to hepatitis B virus infection as a risk factor for hepatocellular carcinoma in Iran. Asian Pac J Cancer Prev, 17, 2395-9.
  4. Azar SS, Mansoori M, Attar M, Shahbazi M. (2016) Tumor necrosis factor alpha-308 G/A single nucleotide polymorphism and susceptibility to hepatocellular carcinoma via hepatitis B infection. Asian Pac J Cancer Prev, 17, 3381-4.
  5. Bahmani MK, Khosravi A, Mobasser A, Ghezelsofla E. (2010) Seroprevalence of hepatitis B virus infection and vaccination compliance among health care workers in Fars Province, Iran. Arch Clin Infect Dis, 5, 45-50.
  6. Cheong JY, Cho SW, Chung SG, et al.( 2006) Genetic polymorphism of interferon-gamma, interferon-gamma receptor, and interferon regulatory factor-1 genes in patients with hepatitis B virus infection. Biochem Genet, 44, 246-55. https://doi.org/10.1007/s10528-006-9029-y
  7. Dean M, Carrington M, Winkler C, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, san francisco city cohort, ALIVE study. Science, 273, 1856-62. https://doi.org/10.1126/science.273.5283.1856
  8. Liang T, Chen E, Tang H (2013). Hepatitis B virus gene mutations and hepatocarcinogenesis. Asian Pac J Cancer Prev, 14, 4509-13. https://doi.org/10.7314/APJCP.2013.14.8.4509
  9. Lu Y, Bao J, Deng Y, et al (2015). Role of IL-18 gene promoter polymorphisms, serum IL-18 levels, and risk of hepatitis B virus-related liver disease in the Guangxi Zhuang population: a retrospective case-control study. Asian Pac J Cancer Prev, 16, 6019-26. https://doi.org/10.7314/APJCP.2015.16.14.6019
  10. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV.(2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med, 192, 921-30. https://doi.org/10.1084/jem.192.7.921
  11. Kazemi Arababadi M, Pourfathollah AA, et al.(2009) Detection of the CCR5-d32 Mutation in Patients Infected with Occult Hepatitis B. Zahedan J Res Med Sci, 11, 94-8.
  12. Khorramdelazad H, Hakimizadeh E, Hassanshahi G, et al.(2013) CCR5 Delta 32 mutation is not prevalent in Iranians with chronic HBV infection. J Med Virol, 85, 964-8. https://doi.org/10.1002/jmv.23510
  13. Murai M , Yoneyama H, Harada A, et al. (1999) Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest, 104, 49-57. https://doi.org/10.1172/JCI6642
  14. Nansen A, Christensen JP, Andreasen SO, et al. (2002)The role of CC chemokine receptor 5 in antiviral immunity. Blood, 99, 1237-45. https://doi.org/10.1182/blood.V99.4.1237
  15. Ng-Cashin J, Kuhns JJ, Burkett SE, et al.(2003) Host absence of CCR5 potentiates dendritic cell vaccination. J Immunol, 170, 4201-8. https://doi.org/10.4049/jimmunol.170.8.4201
  16. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest, 97, 1655-65. https://doi.org/10.1172/JCI118592
  17. Samson M, Libert F, Doranz BJ, et al.(1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382, 722-5. https://doi.org/10.1038/382722a0
  18. Shaban N, Salem H, ElsadanyM, et al (2016). Distribution of glutathione S-transferase omega gene polymorphism with different stages of HBV infection including hepatocellular carcinoma in the egyptian population. Asian Pac J Cancer Prev, 17, 2145-50. https://doi.org/10.7314/APJCP.2016.17.4.2145
  19. Shahbazi M, Ebadi H, Fathi D, et al.(2009) CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol, 29, 1205-9. https://doi.org/10.1007/s10571-009-9415-1
  20. Sriprapun M, Chuaypen N, Khlaiphuengsin A, et al. (2016) Association of PINX1 but not TEP1 polymorphisms with progression to hepatocellular carcinoma in Thai patients with chronic hepatitis B virus infection. Asian Pac J Cancer Prev, 17, 2019-25. https://doi.org/10.7314/APJCP.2016.17.4.2019
  21. Suneetha PV, Sarin SK, Goyal A, et al (2006)Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol, 44, 856-63. https://doi.org/10.1016/j.jhep.2006.01.028
  22. Tancredo as, pleasant, He Yan, et al. (2009)Association of $CCR5-{\Delta}32$ polymorphism with HBV infection in special population of Guizhou Province. Shi Jie Hua Ren Xiao Hua Za Zhi, 17, 2317-9.
  23. Thio CL, Astemborski J, Bashirova A, et al.(2007) Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol, 81, 441-5. https://doi.org/10.1128/JVI.01897-06
  24. Thio CL, Astemborski J, Thomas R, et al.( 2008) Interaction between RANTES promoter variant and $CCR5{\Delta}32$ favors recovery from hepatitis B. J mmunol, 181, 7944-7.
  25. Wanich N, Vilaichone R, Chotivitayatarakorn P, Siramolpiwat S (2016). High prevalence of hepatocellular carcinoma in patients with chronic hepatitis B infection in Thailand. Asian Pac J Cancer Prev, 17, 2857-60.
  26. Wong MM, Fish EN.(2003) Chemokines: attractive mediators of the immune response. Semin Immunol, 15, 5-14. https://doi.org/10.1016/S1044-5323(02)00123-9